Asklepios Group: Stable business performance in Q1 2025

From January to March 2025, the Asklepios Group’s healthcare facilities treated a total of 954,522 patients, 3.8% more than in the same period of the previous year (3M 2024: 919,532). Compared with the same period of the previous year, the number of inpatients treated increased to 196,129 (3M 2024: 196,297). In the area of outpatient care, an increase to 757,393 was recorded (3M 2024: 723,235).

Revenues of the Asklepios Group saw a 10.2% increase to reach EUR 1.56 billion in the first quarter of 2025 (2024: EUR 1.41 billion. Consolidated net income (EAT) for January to March 2025 totalled EUR 22.5 million (3M 2024: EUR 18.5 million). The EAT margin was 1.4% (3M 2024: 1.3%). Investments in the first quarter of 2025 totalled EUR 69.5 million (3M 2024: EUR 67.4 million).

As at 31 March 2025, the Asklepios Group enjoys a stable financial position. The equity capital ratio was 30.4% as at 31 March 2025 (31 December 2024: 30.5%). The net debt ratio stood at 2.8x (31 December 2024: 2.9x).